Gastrointestinal Cancer

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Shubham Pant, MD, MBBS, discusses data for daraxonrasib and its potential impact on pancreatic cancer management.

The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.

The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.

The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX in pancreatic adenocarcinoma.

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.

Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.

In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.

The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.

Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA.

Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.

The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.